The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK.
Cardiovasc Drugs Ther. 2010 Jun;24(3):235-54. doi: 10.1007/s10557-010-6237-9.
A standard ischemic preconditioning (IPC) stimulus of one or more brief episodes of non-lethal myocardial ischemia and reperfusion elicits a bi-phasic pattern of cardioprotection. The first phase manifests almost immediately following the IPC stimulus and lasts for 1-2 h, after which its effect disappears (termed classical or early IPC). The second phase of cardioprotection appears 12-24 h later and lasts for 48-72 h (termed the Second Window of Protection [SWOP] or delayed or late IPC). The cardioprotection conferred by delayed IPC is robust and ubiquitous but is not as powerful as early IPC. Although there are some similarities in the mechanisms underlying early and delayed IPC, one of the major distinctions between the two is the latter's requirement for de novo protein synthesis of distal mediators such as iNOS and COX-2 which mediate the cardioprotection 24 h after the IPC stimulus. The phenomenon of delayed IPC has been demonstrated in man using a variety of experimental models. However, its clinical application has been limited by the same factors which affect early IPC- i.e. the need to intervene before the onset of myocardial ischemia, thereby restricting its potential clinical utility to planned settings of acute myocardial ischemia-reperfusion injury such as coronary artery bypass graft surgery, cardiac transplantation and percutaneous coronary intervention. In this article, the focus will be on the origins of delayed IPC, the mechanisms underlying its delayed cardioprotective effect, and the potential areas for its clinical application.
标准的缺血预处理(IPC)刺激,即一个或多个短暂的非致死性心肌缺血和再灌注,会引发心肌保护的双相模式。第一相几乎在 IPC 刺激后立即显现,持续 1-2 小时,之后其效果消失(称为经典或早期 IPC)。第二相的心肌保护在 12-24 小时后出现,持续 48-72 小时(称为第二保护窗口[SWOP]或延迟或晚期 IPC)。延迟 IPC 赋予的心肌保护是强大且普遍的,但不如早期 IPC 强大。尽管早期和延迟 IPC 的机制有一些相似之处,但两者之间的主要区别之一是后者需要新的远程介质(如 iNOS 和 COX-2)的蛋白合成,这些介质在 IPC 刺激后 24 小时介导心肌保护。延迟 IPC 的现象已在人类中使用各种实验模型得到证明。然而,其临床应用受到了与早期 IPC 相同的因素的限制,即需要在心肌缺血发作之前进行干预,从而将其潜在的临床应用限制在急性心肌缺血再灌注损伤的计划环境中,如冠状动脉旁路移植术、心脏移植和经皮冠状动脉介入治疗。在本文中,重点将放在延迟 IPC 的起源、其延迟性心肌保护作用的机制以及其临床应用的潜在领域。